Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFCT-2003 ALBATROS
2024-512028-12-00Phase 2Authorised
- Sponsor
- IFCT
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by IFCT. Primary endpoint: Objective response rate at 8 weeks by investigator. Planned start Jun 2024; status: authorised.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-512028-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512028-12-00.